DCOY — Decoy Therapeutics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1615219 ·
Last close
$3.11
Market Cap
$2.04M
52W High
$13.51
52W Low
$3.07
ADV30
62,723
Next earnings
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -2,283,739 -2,224,628 8,423,275 7,820,608 4,545,890
Dec 2025 0 -9,034,562 -8,977,655 11,056,707 10,709,937 5,167,738
Sep 2025 0 -895,130 -873,467 6,097,032 4,809,680 1,848,967
Jun 2025 0 -965,565 -957,825 1,392,778 794,886 2,222,502

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,534,803
Investing CF
$964,735
Financing CF
$11,792,296
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-346.97
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-96,666,726
Inventory
Receivables
$200,000
ST Investments
EBIT TTM
$-13,178,996
Pretax Income TTM
$-13,033,575
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$227,629
EBITDA
$-6,074,362
Free Cash Flow
$-509,881
Enterprise Value
$-6,192,516
Total Cash
$8,289,108
Total Debt
$0
Shares Out
655,185
Trailing EPS
$115.98
Book Value
$11.07
ROE
-827.8%
ROA
-73.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -12,613,952 -12,518,480 11,056,707 5,167,738 -4,827,188
Dec 2024 0 -5,734,316 -5,575,777 3,022,974 1,511,279 -4,525,337
Dec 2023 0 -12,894,944 -12,542,693 6,586,523 1,299,241 -12,846,137
Dec 2022 0 -22,975,231 -31,607,956 14,650,799 4,266,191 -17,595,321

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-21,561,494
OpCashFlow TTM
$0
Assets (Latest)
$3,022,974
Forward EPS
$-19.32

Peers — same industry

TickerNameMarket CapLastDaily %
SXTC China SXT Pharmaceuticals, Inc. $2.03M $3.80
SHPH Shuttle Pharmaceuticals Holdings, Inc. $2.06M $3.52
PTIX Protagenic Therapeutics, Inc.\new $1.97M $1.09
CDT CDT Equity Inc. $1.96M $2.49
AGNPF Grey Matters Health Inc. $1.80M $0.33

News headlines (Yahoo Finance, 1h cache)

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
2026-07-15 13:24 · Yahoo
DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?
2026-06-29 15:41 · Yahoo
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
2026-06-27 00:11 · Yahoo
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
2026-06-08 12:00 · Yahoo
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
2026-06-03 12:00 · Yahoo
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
2026-05-26 12:15 · Yahoo
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
2026-04-27 12:45 · Yahoo
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
2026-04-09 12:36 · Yahoo
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
2026-04-06 13:15 · Yahoo
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-04-02 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.